Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation

Atrial fibrillation (AF) is associated with an increased risk of thromboembolism, and is the most prevalent factor for cardioembolic stroke. Vitamin K antagonists (VKAs) have been the standard of care for stroke prevention in patients with AF since the early 1990s. They are very effective for the pr...

Full description

Bibliographic Details
Main Authors:	Huber, K, Connolly, S J, Kher, A, Christory, F, Dan, G-A, Hatala, R, Kiss, R G, Meier, B, Merkely, B, Pieske, B, Potpara, T, Stępińska, J, Klun, N Vene, Vinereanu, D, Widimský, P
Format:	Online
Language:	English
Published:	Blackwell Publishing Ltd 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712459/

id	pubmed-3712459
recordtype	oai_dc
spelling	pubmed-37124592013-07-25 Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation Huber, K Connolly, S J Kher, A Christory, F Dan, G-A Hatala, R Kiss, R G Meier, B Merkely, B Pieske, B Potpara, T Stępińska, J Klun, N Vene Vinereanu, D Widimský, P Cardiovascular Atrial fibrillation (AF) is associated with an increased risk of thromboembolism, and is the most prevalent factor for cardioembolic stroke. Vitamin K antagonists (VKAs) have been the standard of care for stroke prevention in patients with AF since the early 1990s. They are very effective for the prevention of cardioembolic stroke, but are limited by factors such as drug–drug interactions, food interactions, slow onset and offset of action, haemorrhage and need for routine anticoagulation monitoring to maintain a therapeutic international normalised ratio (INR). Multiple new oral anticoagulants have been developed as potential replacements for VKAs for stroke prevention in AF. Most are small synthetic molecules that target thrombin (e.g. dabigatran etexilate) or factor Xa (e.g. rivaroxaban, apixaban, edoxaban, betrixaban, YM150). These drugs have predictable pharmacokinetics that allow fixed dosing without routine laboratory monitoring. Dabigatran etexilate, the first of these new oral anticoagulants to be approved by the United States Food and Drug Administration and the European Medicines Agency for stroke prevention in patients with non-valvular AF, represents an effective and safe alternative to VKAs. Under the auspices of the Regional Anticoagulation Working Group, a multidisciplinary group of experts in thrombosis and haemostasis from Central and Eastern Europe, an expert panel with expertise in AF convened to discuss practical, clinically important issues related to the long-term use of dabigatran for stroke prevention in non-valvular AF. The practical information reviewed in this article will help clinicians make appropriate use of this new therapeutic option in daily clinical practice. Blackwell Publishing Ltd 2013-06 2013-04-05 /pmc/articles/PMC3712459/ /pubmed/23557519 http://dx.doi.org/10.1111/ijcp.12147 Text en Copyright © 2013 Blackwell Publishing Ltd http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Huber, K Connolly, S J Kher, A Christory, F Dan, G-A Hatala, R Kiss, R G Meier, B Merkely, B Pieske, B Potpara, T Stępińska, J Klun, N Vene Vinereanu, D Widimský, P
spellingShingle	Huber, K Connolly, S J Kher, A Christory, F Dan, G-A Hatala, R Kiss, R G Meier, B Merkely, B Pieske, B Potpara, T Stępińska, J Klun, N Vene Vinereanu, D Widimský, P Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation
author_facet	Huber, K Connolly, S J Kher, A Christory, F Dan, G-A Hatala, R Kiss, R G Meier, B Merkely, B Pieske, B Potpara, T Stępińska, J Klun, N Vene Vinereanu, D Widimský, P
author_sort	Huber, K
title	Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation
title_short	Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation
title_full	Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation
title_fullStr	Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation
title_full_unstemmed	Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation
title_sort	practical use of dabigatran etexilate for stroke prevention in atrial fibrillation
description	Atrial fibrillation (AF) is associated with an increased risk of thromboembolism, and is the most prevalent factor for cardioembolic stroke. Vitamin K antagonists (VKAs) have been the standard of care for stroke prevention in patients with AF since the early 1990s. They are very effective for the prevention of cardioembolic stroke, but are limited by factors such as drug–drug interactions, food interactions, slow onset and offset of action, haemorrhage and need for routine anticoagulation monitoring to maintain a therapeutic international normalised ratio (INR). Multiple new oral anticoagulants have been developed as potential replacements for VKAs for stroke prevention in AF. Most are small synthetic molecules that target thrombin (e.g. dabigatran etexilate) or factor Xa (e.g. rivaroxaban, apixaban, edoxaban, betrixaban, YM150). These drugs have predictable pharmacokinetics that allow fixed dosing without routine laboratory monitoring. Dabigatran etexilate, the first of these new oral anticoagulants to be approved by the United States Food and Drug Administration and the European Medicines Agency for stroke prevention in patients with non-valvular AF, represents an effective and safe alternative to VKAs. Under the auspices of the Regional Anticoagulation Working Group, a multidisciplinary group of experts in thrombosis and haemostasis from Central and Eastern Europe, an expert panel with expertise in AF convened to discuss practical, clinically important issues related to the long-term use of dabigatran for stroke prevention in non-valvular AF. The practical information reviewed in this article will help clinicians make appropriate use of this new therapeutic option in daily clinical practice.
publisher	Blackwell Publishing Ltd
publishDate	2013
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712459/
_version_	1611995126451666944

Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation

Similar Items